The Gates Foundation and LifeArc have launched a Grand Challenge to reduce the production costs of monoclonal antibodies (mAbs) to $10 per gram. This initiative invites scientists, engineers, and innovators to propose transformative solutions that improve manufacturing efficiency, lower costs, and increase global access to these life-saving treatments. With funding opportunities available for both proof-of-concept projects and advanced developments, this challenge aims to drive innovation and make high-impact therapies accessible to low- and middle-income countries.
